免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Impact of clinical and histopathological characteristics on the disease-free survival of stage I-II acral melanoma patients.
Impact of clinical and histopathological characteristics on the disease-free survival of stage I-II acral melanoma patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管与晚期相比,I-II 期肢端黑色素瘤的预后较好,但临床与组织病理学特征仍可影响预后。
肢端黑色素瘤较为罕见,与其他部位皮肤黑色素瘤相比预后更差。尽管如此,聚焦肢端黑色素瘤预后的研究仍然较少,尤其是针对初始临床分期患者。本研究旨在评估临床和组织病理学特征对 I–II 期患者无病生存期(DFS)的影响。
分析了 154 例 I–II 期肢端黑色素瘤病例,复核所有病例的组织病理学和临床参数。根据患者在 5 年内是否出现疾病复发进行分组。采用 Cox 比例风险回归分析独立危险因素,并使用 Kaplan–Meier 法计算 DFS 曲线。
5 年内,27.9% 的患者发生疾病复发,其中 90.4% 发生在前 3 年。单变量和多变量分析均未发现临床参数对 DFS 有显著影响。5 年 DFS 率为 72.7%。从初次诊断到疾病复发的中位时间为 21 个月。然而,Breslow 厚度、是否存在溃疡、每 mm² >3 个有丝分裂象、是否存在TIL(肿瘤浸润淋巴细胞)及神经周围侵犯,均与首次复发时间缩短显著相关。
尽管 I–II 期肢端黑色素瘤的预后优于晚期疾病,临床和组织病理学特征仍会影响预后。除 Breslow 厚度和溃疡外,还应关注有丝分裂率、TIL 和神经周围侵犯,以优化初始临床分期肢端黑色素瘤患者的随访。
Acral melanoma is rare and associated with a worse prognosis compared to cutaneous melanoma in other locations. Despite this, few studies have focused on the prognosis of acral melanoma, particularly in patients with initial clinical stage. The aim of this study was to assess the impact of clinical and histopathological characteristics on the disease-free survival (DFS) of stage I-II patients.
We analyzed 154 stage I-II acral melanoma cases, all of whom underwent a review of the histopathological and clinical parameters. Patients were divided into groups based on the presence or absence of disease recurrence within 5 years. We used Cox proportional regression to analyze independent risk factors and computed DFS curves using the Kaplan-Meier method.
Within 5 years, 27.9% of patients experienced disease recurrence, with 90.4% occurring during the first 3 years. Univariate and multivariate analyses did not identify any clinical parameters with a significant influence on DFS. The DFS rate at 5 years was 72.7%. The median duration of disease recurrence after the initial diagnosis was 21 months. However, Breslow thickness, presence of ulceration, >3 mitosis/mm 2 , presence of tumor-infiltrating lymphocytes (TIL), and perineural invasion were significantly associated with a decrease in time to first recurrence.
Despite the favorable prognosis of stage I-II acral melanoma compared with advance stage, clinical and histopathological characteristics can impact prognosis. In addition to Breslow thickness and ulceration, attention should be paid to mitotic rate, presence of TIL, and perineural invasion to optimize follow-up of acral melanoma patients diagnosed in the initial clinical stage.
MEMBER ACCOUNT
登录成功会直接打开下一页。